Progress update: Pharmacological treatment of Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 5, 2007, Pages 569-578

  Hogan, David B ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Drug therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DICLOFENAC; DIMENHYDRINATE; DONEPEZIL; FLURBIPROFEN; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IDEBENONE; INDOMETACIN; LEVO FLURBIPROFEN; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROCHLORPERAZINE; PYRIDOXINE; RIVASTIGMINE; SELEGILINE; SULINDAC; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GINKGO BILOBA; HALLUCINATION; HUMAN; INSOMNIA; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NIGHTMARE; NONHUMAN; REVIEW; SINUS BRADYCARDIA; SLEEP DISORDER; SYNCOPE; UNSPECIFIED SIDE EFFECT; VIVID DREAM; VOMITING;

EID: 36049000202     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Aisen PS, Davis KL, Berg JD, et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology, 54:588-93.
2. Aisen PS, Schafer KA, Grundman M, et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289:2819-26.
3. Almeida OP, Flicker L. 2003. Testosterone and dementia: too much ado about too little data. J Br Menopause Soc, 9:107-10.
4. Anonymous. 2006. NICE faces legal challenge over restriction on dementia drugs. BMJ, 333:1085.
5. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. 2002. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin, 18:129-38.
6. Balk EM, Raman G, Tatsioni A, et al. 2007. Vitamin B6, B 12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med, 167:21-30.
7. Bartorelli L, Giraldi C, Saccardo M, et al. 2005. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin, 21:1809-18.
8. Bent S, Goldberg H, Padula A, et al. 2005. Spontaneous bleeding associated with Ginkgo biloba - a case report and systematic review of the literature. J Gen Intern Med, 20:657-61.
9. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, (1):CD005593.
10. Birks J, Grimley Evans J, lakovidou V, et al. 2000. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev, (4):CD001191.
11. Birks J, Grinley EV, Van Dongen M. 2002. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev, (4):CD003120.
12. Birks J, Harvey R. 2006. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev, (1):CD001190.
13. Bordier P, Garrigue S, Barold SS, et al. 2003. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace, 5:429-31.
14. Bordier P, Lanusse S, GaTrigue S, et al. 2005. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging, 22:687-94.
15. Bullock R, Connolly C. 2002. Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry, 17:288-9.
16. Bullock R, Touchon J, Bergman H, et al. 2005. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin, 21:1317-27.
17. Burns A, O'Brien J. 2006. on behalf of the BAP Dementia Consensus Group Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, 20:732-55.
18. Cherrier MM, Matsumoto AM, Amory JK, et al. 2005. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology, 64:2063-8.
19. Chohan MO, Iqbal K. 2006. From tau to toxicity: Emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis, 10:81-7.
20. Clegg A, Bryant J, Nicholson T, et al. 2002. Clinical and cost-effectiveness of donepezil, rivastigtriine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care, 18:497-507.
21. Cosman KM, Boyle LL, Porsteinsson AP. 2007. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother, 8:203-14.
22. Courtney C, Farrell D, Gray R, et al. 2004. Long-term donepezil. treatment in 565 patients with Alzheimer's disease (AD2000): randomised doubleblind trial. Lancet, 363:2105-15.
23. Creeley CE, Wozniak DF, Nardi A, et al. 2006. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging, [Epub ahead of print].
24. Dantome T, Aunacombe S, Sarazin M, et al. 2006. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract, 60:110-18.
25. Doody RS, Geldmacher DS, Gordon B, et al. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol, 58:427-3.
26. Doody RS, Stevens JC, Beck C, et al. 2001. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcomnuttee of the American Academy of Neurology. Neurology, 56:1154-66.
27. Dybicz SB, Keohane DJ, Erwin WG, et al. 2006. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother, 4:154-60.
28. Emre M. 2002. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl, (127):64-72.
29. Farlow MR, Cummings JL. 2007. Effective pharmacologic management of Alzheimer's disease. Am J Med, 120:388-97.
30. Firuzi O, Praticò D. 2006. Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol, 59:219-28.
31. Gauthier S, Emre M, Farlow MR, et al. 2003. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin, 19:707-14.
32. Garrard J, Harris S, Eberly LE, Matiak A. 2003. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med, 163:2290-5.
33. Gill SS, Mamdani M, Naglie G, et al. 2005. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med, 165:808-13.
34. Gillette-Guyonnet S, Cortes F, Cantet C, et al. 2005. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort. J Nutr Health Aging, 9:69-73.
35. Goedert M, Spillantini MG. 2006. A Century of Alzheimer's Disease. Science, 314:777-81.
36. Green C, Picot J, Loveman E, et al. 2005. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics, 23:1271-82.
37. Grossberg GT, Edwards KR, Zhao Q. 2006. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J Clin Pharmacol, 46:17S-26S.
38. Heart Protection Study Collaborative Group. 2002.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
39. Henderson VW, Hogervorst E. 2004. Testosterone and Alzheimer disease. Is it men's turn now? Neurology, 62:170-1.
40. Hogan DB, Patterson C. 2002. Progress in clinical neurosciences - treatment of Alzheimer's disease and other dementias - review and comparison of the cholinesterase inhibitors. Can J Neurol Sci, 29:306-14.
41. Hogan DB, Goldlist B, Naglie G, et al. 2004. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol, 3:622-6.
42. Hogervorst E, Yaffe K, Richards M, et al. 2002. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev, (3):CD003799.
43. Imbimbo BP. 2004. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs, 13:1469-81.
44. Ioannidis JPA. 2006. Indirect comparisons: the mesh and mess of clinical trials. Lancet, 368:1470-2.
45. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ, 331:321-7.
46. Kanowski S, Hoerr R. 2003. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry, 36:297-303.
47. Kogut SJ, El-Maouche D, Abughosh SM. 2005. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy, 25:1729-35.
48. Kurz A, Van Baelen B. 2004. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane Collaboration. Dement Geriatr Cogn Disord, 18:217-26.
49. Lanctôt KL, Herrmann N, Yau M et al. 2003. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ, 169:557-64.
50. Loy C, Schneider L. 2006. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, (1):D001747.
51. Lu CJ, Tune LE. 2003. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry, 11:458-61.
52. Malouf M, Grimley EJ, Areosa SA. 2003. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev, (4):CD004514.
53. Malouf R, Grimley Evans J. 2003. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev, (4):CD004393.
54. Malouf R, Areosa SA. 2003. Vitamin B12 for cognition. Cochrane Database Syst Rev, (3):CD004326.
55. Mazza M, Capuano A, Bria P, Mazza S. 2006. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol, 13:981-5.
56. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47:425-32.
57. McShane R, Areosa Sastre A, Minakaran N. 2006. Memantine for dementia. Cochrane Database Syst Rev, (2):CD003154.
58. Miller ER, Pastor-Barriuso, R, Dalai D, et al. 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med, 142:37-46.
59. Moffat SD, Zonderman AB, Metter EJ, et al. 2004. Free testosterone and risk for Alzheimer disease in older men. Neurology, 62:188-93.
60. Morris CA, Avorn J. 2003. Internet marketing of herbal products. JAMA, 290:1505-9.
61. National Institute for Health and Clinical Excellence. 2006. NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease [online]. Accessed January 15, 2007. URL: http://www.nice.org.uk/TA111.
62. Newby VJ, Kenny A, Grant I, et al. 2004. Donepezil and cardiac syncope: case report. Int J Geriatr Psychiatry, 19:1110-12.
63. Patterson C, Gauthier S, Bergman H, et al. 2001. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci, 28 (Suppl 1):S3-16.
64. Peskind ER, Potkin SG, Pomari N, et al. 2006. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry, 14:704-15.
65. Petersen RC, Thomas RG, Grundman M, et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med, 352:2379-88.
66. Priano L, Gasco MR, Mauro A. 2006. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging, 23:357-75.
67. Ramsden M, Shin TM, Pike CJ. 2003. Androgens modulate neuronal vulnerability to kainite lesion. Neuroscience, 122:573-8.
68. Reines SA, Block GA, Morris JC, et al. 2004. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 62:66-71.
69. Riepe MW, Adler G, Ibach B, et al. 2006. Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry, 8:258-63.
70. Ritchie CW, Ames D, Clayton T, et al. 2004. Meta-analysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry, 12:358-69.
71. Rockwood K. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 75:677-85.
72. Rogers J, Kirby LC, Hempelman SR, et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43:1609-11.
73. Sadowsky CH, Farlow MR, Atkinson L, et al. 2005. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry, 7:43-8.
74. Sano M, Ernesto C, Thomas RG, et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med, 336:1216-22.
75. Scharf S, Mander A, Ugoni A, et al. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 53:197-201.
76. Schmitt F, Ryan M, Cooper G. 2007. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin Drug Metab Toxicol, 3:135-41.
77. Schneider LS, Dekosky ST, Farlow MR, et al. 2005. A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alz Res, 2:541-55.
78. Seshadri S, Beiser A, Selhub J, et al. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 346:476-83.
79. Shepherd J, Blauw GJ, Murphy MB, et al. 2002. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360:1623-30.
80. Simons M, Schw5xzler F, Lfitjohann D, et al. 2002. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol, 52:346-50.
81. Sparks DL, Sabbagh MN, Connor DJ, et al. 2005. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol, 62:753-7.
82. Stahl SM, Markowitz JS, Gutterman EM, et al. 2003. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry, 64:466-72.
83. Suleyman T, Tevfik P, Abdulkadir G, et al. 2006. Complete atrioventricular block and ventricular tachyarrhyffimia associated with donepezil. Emerg Med J, 23:641-2.
84. Summers WK, Majovski LV, Marsh GM, et al. 1986. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med, 315:1241-5.
85. Tabet N, Birks J, Grimley Evans J, et al. 2000. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev, (4):CD002854.
86. Tabet N, Feldman H. 2002. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev, (2):CD003673.
87. Tan RS, Pu SJ. 2003. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male, 6:13-17.
88. Tariot PN, Solomon PR, Morris JC, et al. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54:2269-76.
89. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291:317-24.
90. Taylor AM, Hoehns JD, Anderson DM, et al. 2002. Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother, 36:1550-3.
91. Thal LJ, Grundman M, Berg J, et al. 2003. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology, 61:1498-502.
92. Thompson S, Lanct6t KL, Herrmann N. 2004. The benefits and risks associated with cholinesterase inhibitor therapy in Alzhenner's disease. Expert Opin Drug Saf 3:425-40.
93. Trinh NH, Hoblyn J, Mohanty S, et al. 2003. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA, 289:210-16.
94. van Dongen, van Rossum E, Kessels A, et al. 2003. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol, 56:367-76.
95. Van Dyck CH, Schmitt FA, Olin JT, et al 2006. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 14:428-37.
96. van Gool WA, Weinstein HC, Scheltens PK, et al. 200 1. Effect of hydroxy-chloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet, 358:455-60.
97. Waldemar G, Dubois B, Emre M, et al. 2007. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol, 14:e1-26.
98. Whitehead A, Perdomo C, Pratt RD, et al. 2004. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry, 19:624-33.
99. Wilkinson DG, Howe 1. 2005. Switching from donepezil to galantamine: a double-blind study of two wash-out periods. Int J Geriatr Psychiatry, 20:489-91.
100. Winblad B, Kilander L, Erikssori S, et al. 2006. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367:1057-65.
101. Winblad B, Jelic V, Kershaw P, et al. 2007. Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging, 24:57-61.
102. Wolfson C, Oremus M, Shukla V, et al. 2002. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther, 24:862-86.
103. Wolfson C, Perrault A, Moride Y, et al. 2002. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology, 21:81-6.